Influenza Infection of the Embryonated Hen's Egg: An alternative model for in vivo evaluation of antiviral compounds

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 2, 2004, Pages 130-134

  Härtl, Albert ^a   Sauerbrei, Andreas ^b   Stelzner, Axel ^a   Wutzler, Peter ^b  

^a HANS KNÖLL INSTITUTE   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Amantadine; Antiviral drugs; In vivo model, alternative, embryonated hen's egg; Influenza a virus infection; Rimantadine; Zanamivir

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; CAS 139110808; CAS 1501844; CAS 665667; INFLUENZA VACCINE; RIMANTADINE; ZANAMIVIR;

ANIMAL TISSUE; ARTICLE; CHICK EMBRYO; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; EXPERIMENTAL INFECTION; HEN; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A; LETHALITY; NONHUMAN; RELIABILITY; SURVIVAL; ZYGOTE;

EID: 1342326874     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296948     Document Type: Article

References (25)

1. De Clercq, E., Antiviral drugs: current state of art. J. Clin. Virol. 22, 73 (2001)
2. Zak, O., Sande, M. E., Handbook of animal models of infection. Experimental models in antimicrobial chemotherapy. Academic Press, San Diego - London (1999)
3. Govorkova, E. A., Kodihalli, S., Alymova, I. V. et al., Growth and immunogenicity of influenza viruses cultivated in vero or MDCK cells and in embryonated chicken eggs, in: Inactivated influenza vaccines prepared in cell culture, F. Brown, J. S. Robertson, G. C. Schild et al. (eds.), Developmental Biological Standards, pp. 39-51. Karger, Basel (1999)
4. Pine, L., Quinn, F. D., Ewing, E.P. Jr. et al., Evaluation of the chick embryo for determination of relative virulence of Neisseria meningitidis. FEMS Microbiol. Lett. 130, 37 (1995)
5. Schirren, C., Rieth, H., Koch, H., Tierexperimentelle Untersuchungen zur Pathogenität von Hefepilzen. Arch. klin. exp. Dermatol. 210, 86 (1960)
6. Härtl, A., Hillesheim, H. G., Künkel, W. et al., Das Candida-infizierte Hühnerei: Ein alternatives Testsystem zum Nachweis systemischer Anticandida-Wirkung. Arzneim.-Forsch./Drug Res. 45 (II), 926 (1995)
7. Härtl, A., Möllmann, U., Schrinner, E. et al., Pseudomonas aeruginosa infection in embryonated hen's egg / An alternative in vivo model for the screening of antibacterial substances. Arzneim.-Forsch./Drug Res. 47 (II), 1061 (1997)
8. Partridge, B. M., The use of the chorioallantoic membrane of the developing chick for culture of dermatophytes - A modified technique. A preliminary report upon its use for serial passage. J. Invest. Dermatol. 32, 605 (1959)
9. Grunert, R. R., Hoffmann, C. E., Sensitivity of influenza A/New Jersey/8/76 (Hsw1N1) virus to amantadine HCl. J. Infect. Dis. 136, 297 (1977)
10. Zhirnov, O. P., Ovcharenko, A. V., Bukrinskaya, A. G., Myxovirus replication in chicken embryos can be suppressed by aprotinin due to the blockage of viral glycoprotein cleavage. J. Gen. Virol. 66, 1633 (1985)
11. Mochalova, L. V., Tuzikov, A. B., Marinina, V. P. et al., Synthetic polymeric inhibitors of influenza virus receptor-binding activity suppress virus replication. Antiviral Res. 23, 179 (1994)
12. Sidwell, R. W., The mouse model of influenza virus infection, in: Handbook of animal models of infection. Experimental models in antimicrobial chemotherapy, O. Zak, M. A. Sande (eds.), pp. 981-987. Academic Press, San Diego - London (1999)
13. Sweet, C., Fenton, R. J., Price, G. E., The ferret as animal model of influenza virus infection, in: Handbook of animal models of infection. Experimental models in antimicrobial chemotherapy; O. Zak, M. A. Sande (eds.), pp. 989-998. Academic Press, San Diego - London (1999)
14. Ribatti, D., Vacca, A., Roncali, L. et al., The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis. Curr. Pharm. Biotechnol. 1, 73 (2000)
15. Sidwell, R. W., Smee, D. F., In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res. 48, 1 (2000)
16. Bolls, M., Ridell, R. J., Worden, A. N., Animals and alternatives in toxicity testing. Academic Press, London - New York (1983)
17. Bundesminister für Jugend, Familie und Gesundheit, Tierversuchsprobleme und Lösungsmöglichkeiten, Bonn (1982)
18. Fleming, D. M., Managing influenza: amantadine, rimantadine and beyond. Int. J. Clin. Pract. 55, 189 (2001)
19. Davis, W. L., Grunert, R. R., Haff, R. F. et al., Antiviral activity of 1-adamantanamine (amantadine). Science 144, 862 (1964)
20. Grunert, R. R., McGahern, J. W., Davies, W. L., The in vivo antiviral activity of 1-adamantan-amine (amantadine). I. Prophylactic and therapeutic activity against influenza viruses. Virology 26, 262 (1965)
21. Stephen, E. L., Dominik, J. W., Moe, J. B. et al., Treatment of influenza infection of mice by using rimantadine hydrochlorides by aerosol and intraperitoneal routes. Antimicrob. Agents Chemother. 8, 154 (1975)
22. Wang, C., Takeuchi, K., Pinto, L. H. et al., Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol. 67, 5585 (1993)
23. Gubareva, L. V., Kaiser, L., Hayden, F. G., Influenza virus neuraminidase inhibitors. Lancet 355, 827 (2000)
24. Fenton, R. J., Morley, P. J., Owens, I. J. et al., Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract. Antmicrob. Agents Chemother. 43, 2642 (1999)
25. McGahen, J. W., Hoffmann, C. E., Influenza infections of mice. I. Curative activity of amantadine HCl (33395). Proc. Soc. Exp. Biol. Med. 129, 678 (1968)